Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) released its earnings results on Tuesday. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18), FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 109.93% and a negative net margin of 611.47%.

Bolt Biotherapeutics Stock Down 1.6%

Bolt Biotherapeutics stock traded down $0.06 during mid-day trading on Thursday, reaching $3.40. 4,798 shares of the company were exchanged, compared to its average volume of 25,909. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The firm has a market cap of $6.52 million, a P/E ratio of -0.21 and a beta of 1.18. The business has a fifty day moving average of $4.12 and a 200 day moving average of $4.62. Bolt Biotherapeutics has a 12-month low of $3.13 and a 12-month high of $7.20.

Analysts Set New Price Targets

BOLT has been the topic of several analyst reports. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $34.67.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BOLT. Squarepoint Ops LLC grew its position in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics during the third quarter valued at approximately $85,000. Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics in the third quarter valued at approximately $89,000. Finally, Renaissance Technologies LLC boosted its stake in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.